


## What is claimed is:

- 1. A polynucleotide sequence encoding a polypeptide that is a portion of the flaA gene of Campylobacter, said polynucleotide sequence consisting of all or a portion of the DNA sequence of SEQ ID NO.: 1.
- 2. A recombinant FlaA polypeptide consisting of all or a portion of amino acid sequence SEQ ID NO.: 2.
- 3. A DNA sequence that, because of degeneracy, encodes a polypeptide consisting of all or a portion of amino acid sequence according to Claim-2.
- An expression system consisting of an expression vector wherein the polypeptide of Claim 1 is inserted.
- 5. The expression system of Claim 4 wherein the expression vector is selected from the group consisting of plasmid and viral and E.coli expression vectors.
- 6. An expression system of Claim 5 wherein the plasmid vector is selected from the group consisting of pMal-c2, pMal-p2, and pET.
- 7. An expression system of Claim 4 wherein the viral expression vector of Claim 5 is selected from the group consisting of adenovirus, M13, herpesvirus, vaccinia virus and baculovirus.
- 8. A method for inducing an immune response to FlaA comprising administering the polypeptide of Claim 2 to a subject.
- 9. The method of Claim 8 wherein the polypeptide is administered in conjunction with other

ıĎ.

20

5





PATENT APPLICATION Atty Docket No. NC 78,560

known vaccines to form a multivalent formulation.

- 10. The method of Claim 8 wherein the polypeptide is administered as an injectable formulation.
- 11. The method of Claim 8 wherein the polypeptide is adminstered as an intranasal formulation.
- 12. The method of Claim 8 wherein the polypeptide is administered as an oral formulation.
- 13. The method of Claim 8 wherein administering the polypeptide to subjects has no or reduced ability to induce GBS.
- 14. A method of reducing campylobacter intestinal colonization in a subject, said method comprising administering an immunogenically effective amount of MBP-FlaA with or without an adjuvant.
- 15. A method of reducing campylobacter intestinal colonization in a subject, said method comprising administering an immunogenically effective amount of MBP-FlaA + LT<sub>R192G</sub>.

